In this guide
What is AREDS2 Formula?
The current AREDS2 formula contains vitamin C 500 mg, vitamin E 400 IU, lutein 10 mg, zeaxanthin 2 mg, zinc 80 mg and copper 2 mg daily. It arose from trials in people with intermediate AMD or advanced AMD in one eye. Products that change ingredients or amounts are not the studied formula. [1], [4]
Typical AREDS2 Formula Protocols
| Source and question | Preparation | Amount each administration | Daily total | Frequency and duration | Main interpretation |
|---|---|---|---|---|---|
| Current NEI AREDS2 formula | Six-ingredient oral formula | Label may divide the daily total across capsules | Vitamin C 500 mg; vitamin E 400 IU; lutein 10 mg; zeaxanthin 2 mg; zinc 80 mg; copper 2 mg | Daily; capsule count depends on finished product | For defined AMD stages after eye-professional review; not primary prevention |
| AREDS2 2013 · phase 3 RCT · 4,203 | Background AREDS plus lutein/zeaxanthin, omega-3s, both or placebo | 10 mg lutein plus 2 mg zeaxanthin; or DHA 350 mg plus EPA 650 mg | Same daily totals | Daily; median follow-up 5 years | Neither addition significantly reduced advanced AMD in the primary analysis |
| AREDS2 secondary formula comparison | Lutein/zeaxanthin without beta-carotene versus beta-carotene-containing formulation | 10 mg plus 2 mg | 12 mg carotenoids/day | Daily during trial follow-up | Supported replacing beta-carotene; interpret as secondary comparison, not the primary factorial endpoint |
- Exact product
- Record species, form, lot and co-ingredients.
- Each administration
- Keep amount, timing and context.
- Real endpoint
- Separate biomarker, symptom and clinical outcome.
What is it commonly used for?
The original AREDS antioxidant-and-zinc formula lowered progression to advanced AMD by about 25% over five years in the trial’s higher-risk categories. AREDS2 then tested adding lutein/zeaxanthin or omega-3s and changing beta-carotene and zinc. The primary addition comparisons were null. Secondary comparisons and lung-cancer findings supported replacing beta-carotene with lutein plus zeaxanthin, particularly for current or former smokers. NEI does not recommend the formula to prevent AMD in people without qualifying retinal findings. [1], [2], [4]
One result answers one question
How do forms and labels differ?
Match all six label amounts, not the product name. Some products use 25 mg instead of 80 mg zinc, add omega-3s, retain beta-carotene or omit copper. Those changes may be reasonable in an individual plan but are not identical to the current NEI table. Avoid duplicate vitamin E, zinc or other nutrients across products. [4], [5]
How should the product be stored?
Follow the finished product’s label, keep it dry in its original container and away from children. Discard an expired, heat-damaged, broken-seal or untraceable product.
What does human research show?
| Question | Best direct evidence | Finding | Boundary |
|---|---|---|---|
| Efficacy | Current NEI AREDS2 formula | For defined AMD stages after eye-professional review; not primary prevention | Specific product and population |
| Replication | Limited evidence | No universal effect established | Variable formulations |
| Universal dose? | None | Not established | Rows cannot be combined |
Keep the finished product reviewable
What are the risks and interactions?
Current and former smokers should avoid legacy beta-carotene formulas because lung-cancer incidence was higher. Zinc can cause gastrointestinal effects and affect copper balance; copper was included to reduce zinc-related deficiency risk. Vitamin E and multi-ingredient exposure require review with anticoagulants, surgery, kidney disease and other supplements. Sudden retinal symptoms need urgent care. [2], [3], [5], [6]
Seek urgent eye care for sudden vision loss, a curtain or shadow, new flashes or many floaters, severe eye pain, new central distortion or a rapidly enlarging dark spot.
What is the legal and regulatory status?
In the United States, it is sold as a dietary supplement; FDA does not approve it for safety and effectiveness before sale. In Canada, verify the exact product, NPN and authorized label. Legal sale does not prove efficacy or sport suitability. [6]
When should use stop?
Stop for any allergic reaction, persistent symptom worsening, unexpected laboratory result or doubt about product identity.
What should be monitored?
Confirm AMD category with an eye professional before use. Photograph the Supplement Facts panel and record all six ingredients, daily capsule count, smoking history, other vitamins and medicines. Follow the retinal examination and imaging schedule; the app supports adherence review but does not detect progression.
What can community experience add?
Reports can compare capsule count, cost, nausea and label substitutions. They cannot stage AMD or establish that a look-alike product slows progression. No systematic current community sample was assembled.
How do related options compare?
| Option | Main distinction |
|---|---|
| Current AREDS2 | Lutein and zeaxanthin, no beta-carotene |
| Original AREDS | Contained beta-carotene; unsuitable for current or former smokers |
| Eye multivitamin | Name alone does not establish formula equivalence |
Common questions
Who should consider AREDS2?
People with specific intermediate or advanced AMD findings after eye-professional review.
Does it prevent AMD in healthy eyes?
NEI does not recommend it as primary prevention.
Why is beta-carotene absent?
Current and former smokers had a lung-cancer concern, and secondary comparisons supported lutein/zeaxanthin replacement.
Is 25 mg zinc the same formula?
No. AREDS2 tested lower zinc without a clear efficacy difference, but the current NEI table lists 80 mg.
Can any eye vitamin substitute?
Only if every ingredient and amount match the intended plan.
What should be monitored?
AMD stage, full label, duplicate nutrients, smoking history, adherence and retinal follow-up.
Glossary
Terms for reading the evidence.
- Endpoint
- A defined result measured in a study.
- Anaphylaxis
- A potentially life-threatening systemic allergic reaction.
- Biomarker
- A biological measure that does not guarantee clinical benefit.
- Standardization
- A measured specification for a product component.
- Cross-reactivity
- Immune recognition of related proteins from different sources.
How this guide was researched
NCBI identities, publication notices, indexed abstracts and available open methods were checked. Null outcomes, mixed products, surrogate endpoints and missing details remain visible.
Research record · checked October 9, 2026
Identity: NCBI EFetch verified all indexed records, journal fields, DOI and descendant notices. PMID 23644932 links the JAMA correction DOI 10.1001/jama.2013.6403 for two tables.
Correction: the notice removed the MedDRA qualifier from the Table 3 incident-lung-neoplasm label and replaced all six values in the Table 4 incident-lung-neoplasm row. No affected lung-neoplasm count is used; the primary AMD conclusion and protocol were not the corrected fields.
Methods: open cataract and cognition reports were read. Primary, post hoc and biomarker outcomes remain separated.
Explore the sources
Primary human evidence and official context.
Showing 6 sources
- 01
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. ↗
Phase 3 randomized controlled trial
In 4,203 high-risk participants, adding 10 mg lutein plus 2 mg zeaxanthin to the background AREDS formulation did not significantly reduce advanced AMD in the primary analysis.
- 02
A double-blind, placebo-controlled study on the effects of lutein and zeaxanthin on photostress recovery, glare disability, and chromatic contrast. ↗
Randomized controlled trial
One hundred fifteen healthy young adults were randomized to 10 mg lutein plus 2 mg zeaxanthin or placebo daily for one year; photostress and chromatic contrast improved, while glare disability did not significantly improve.
- 03
Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4. ↗
Randomized cataract analysis
In 4,203 AREDS2 participants, lutein plus zeaxanthin did not significantly reduce cataract surgery or vision loss in the primary analysis.
- 04
Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial. ↗
Randomized cognitive analysis
Among older AREDS2 participants, 10 mg lutein plus 2 mg zeaxanthin did not significantly change the yearly cognitive composite versus no lutein/zeaxanthin.
- 05
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration. ↗
Post hoc trial analysis
A post hoc AREDS/AREDS2 analysis found slower movement of geographic atrophy toward the fovea without a significant change in total atrophy area; this was not a prespecified primary trial outcome.
- 06
AREDS/AREDS2 Frequently Asked Questions ↗
Official clinical guidance
NEI limits AREDS2 use to people with defined AMD stages, gives the exact formula and advises eye-care-professional review; it is not for preventing AMD in people without those findings.
No matching sources
Try a different term or show the full list.
Editorial note
This guide separates composition, biomarker, symptom and clinical outcome. It does not turn a narrow signal into a general promise.